Health

#SFHS2610168VNotice Regarding Pharmaceutical Specialty Prices

🇫🇷France··Other·Low Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This notice outlines the new prices for certain pharmaceutical products, effective from April 15, 2026, focusing on the drug Apremilast in various dosages and package types. It mainly impacts pharmaceutical companies and possibly healthcare providers who purchase these medications.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • New prices set for Apremilast pharmaceutical products starting April 15, 2026
  • Prices specified for different dosages and package types
  • Applies to products from Laboratoires KRKA France

Obligations

What this law requires

high

Apply the price of 99,86 € (PPTTC) to APREMILAST HCS 10/20/30 mg initiation pack (27 tablets) with CIP 34009 303 070 8 starting April 15, 2026

KRKA FRANCE laboratories and pharmaceutical distributors/retailers
operational
high

Apply the price of 205,86 € (PPTTC) to APREMILAST HCS 30 mg tablets (box of 56) with CIP 34009 303 071 0 starting April 15, 2026

KRKA FRANCE laboratories and pharmaceutical distributors/retailers
operational
high

Apply the wholesale price (PFHT) of 82,94 € to APREMILAST HCS initiation pack (27 tablets) starting April 15, 2026

KRKA FRANCE laboratories and pharmaceutical wholesalers
operational
high

Apply the wholesale price (PFHT) of 172,03 € to APREMILAST HCS 30 mg tablets (box of 56) starting April 15, 2026

KRKA FRANCE laboratories and pharmaceutical wholesalers
operational

Affected Parties

Pharmaceutical companiesHealthcare providers

Tags

pharmaceutical,pricing,healthcare